Neuroblastoma – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Neuroblastoma – Pipeline Review, H1 2017’, provides an overview of the Neuroblastoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Neuroblastoma

The report reviews pipeline therapeutics for Neuroblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Neuroblastoma therapeutics and enlists all their major and minor projects

The report assesses Neuroblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Neuroblastoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neuroblastoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ability Pharmaceuticals SL

Actuate Therapeutics Inc

Advanced Accelerator Applications SA

Alissa Pharma

Ampio Pharmaceuticals Inc

APAvadis Biotechnologies Srl

APEIRON Biologics AG

AstraZeneca Plc

Bayer AG

Bellicum Pharmaceuticals Inc

Bexion Pharmaceuticals LLC

BioLineRx Ltd

Biotec Pharmacon ASA

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Cancer Prevention Pharmaceuticals Inc

Cebiotex SL

Celgene Corp

Celldex Therapeutics Inc

Cielo Therapeutics Inc

Cleveland BioLabs Inc

CorMedix Inc

Curis Inc

Cyclacel Pharmaceuticals Inc

DEKK-TEC Inc

EnGeneIC Ltd

Errant Gene Therapeutics LLC

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Green Cross Cell Corp

Ignyta Inc

Juno Therapeutics Inc

Lindis Biotech GmbH

MabVax Therapeutics Holdings Inc

MacroGenics Inc

MediaPharma srl

Merck & Co Inc

Merrimack Pharmaceuticals Inc

Morphogenesis Inc

Novartis AG

Novogen Ltd

OGD2 Pharma SAS

Pfizer Inc

Phylogica Ltd

Progenics Pharmaceuticals Inc

Recombio SL

Ribomic Inc

Sapience Therapeutics Inc

Sareum Holdings Plc

Shionogi & Co Ltd

Sierra Oncology Inc

Syros Pharmaceuticals Inc

Tiltan Pharma Ltd

Trovagene Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Neuroblastoma - Overview 6

Neuroblastoma - Therapeutics Development 7

Neuroblastoma - Therapeutics Assessment 23

Neuroblastoma - Companies Involved in Therapeutics Development 37

Neuroblastoma - Drug Profiles 64

Neuroblastoma - Dormant Projects 390

Neuroblastoma - Discontinued Products 393

Neuroblastoma - Product Development Milestones 394

Appendix 404

List of Tables

List of Tables

Number of Products under Development for Neuroblastoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Neuroblastoma – Pipeline by Ability Pharmaceuticals SL, H1 2017

Neuroblastoma – Pipeline by Actuate Therapeutics Inc, H1 2017

Neuroblastoma – Pipeline by Advanced Accelerator Applications SA, H1 2017

Neuroblastoma – Pipeline by Alissa Pharma, H1 2017

Neuroblastoma – Pipeline by Ampio Pharmaceuticals Inc, H1 2017

Neuroblastoma – Pipeline by APAvadis Biotechnologies Srl, H1 2017

Neuroblastoma – Pipeline by APEIRON Biologics AG, H1 2017

Neuroblastoma – Pipeline by AstraZeneca Plc, H1 2017

Neuroblastoma – Pipeline by Bayer AG, H1 2017

Neuroblastoma – Pipeline by Bellicum Pharmaceuticals Inc, H1 2017

Neuroblastoma – Pipeline by Bexion Pharmaceuticals LLC, H1 2017

Neuroblastoma – Pipeline by BioLineRx Ltd, H1 2017

Neuroblastoma – Pipeline by Biotec Pharmacon ASA, H1 2017

Neuroblastoma – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Neuroblastoma – Pipeline by Bristol-Myers Squibb Company, H1 2017

Neuroblastoma – Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017

Neuroblastoma – Pipeline by Cebiotex SL, H1 2017

Neuroblastoma – Pipeline by Celgene Corp, H1 2017

Neuroblastoma – Pipeline by Celldex Therapeutics Inc, H1 2017

Neuroblastoma – Pipeline by Cielo Therapeutics Inc, H1 2017

Neuroblastoma – Pipeline by Cleveland BioLabs Inc, H1 2017

Neuroblastoma – Pipeline by CorMedix Inc, H1 2017

Neuroblastoma – Pipeline by Curis Inc, H1 2017

Neuroblastoma – Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017

Neuroblastoma – Pipeline by DEKK-TEC Inc, H1 2017

Neuroblastoma – Pipeline by EnGeneIC Ltd, H1 2017

Neuroblastoma – Pipeline by Errant Gene Therapeutics LLC, H1 2017

Neuroblastoma – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Neuroblastoma – Pipeline by GlaxoSmithKline Plc, H1 2017

Neuroblastoma – Pipeline by Green Cross Cell Corp, H1 2017

Neuroblastoma – Pipeline by Ignyta Inc, H1 2017

Neuroblastoma – Pipeline by Juno Therapeutics Inc, H1 2017

Neuroblastoma – Pipeline by Lindis Biotech GmbH, H1 2017

Neuroblastoma – Pipeline by MabVax Therapeutics Holdings Inc, H1 2017

Neuroblastoma – Pipeline by MacroGenics Inc, H1 2017

Neuroblastoma – Pipeline by MediaPharma srl, H1 2017

Neuroblastoma – Pipeline by Merck & Co Inc, H1 2017

Neuroblastoma – Pipeline by Merrimack Pharmaceuticals Inc, H1 2017

Neuroblastoma – Pipeline by Morphogenesis Inc, H1 2017

Neuroblastoma – Pipeline by Novartis AG, H1 2017

Neuroblastoma – Pipeline by Novogen Ltd, H1 2017

Neuroblastoma – Pipeline by OGD2 Pharma SAS, H1 2017

Neuroblastoma – Pipeline by Pfizer Inc, H1 2017

Neuroblastoma – Pipeline by Phylogica Ltd, H1 2017

Neuroblastoma – Pipeline by Progenics Pharmaceuticals Inc, H1 2017

Neuroblastoma – Pipeline by Recombio SL, H1 2017

Neuroblastoma – Pipeline by Ribomic Inc, H1 2017

Neuroblastoma – Pipeline by Sapience Therapeutics Inc, H1 2017

Neuroblastoma – Pipeline by Sareum Holdings Plc, H1 2017

Neuroblastoma – Pipeline by Shionogi & Co Ltd, H1 2017

Neuroblastoma – Pipeline by Sierra Oncology Inc, H1 2017

Neuroblastoma – Pipeline by Syros Pharmaceuticals Inc, H1 2017

Neuroblastoma – Pipeline by Tiltan Pharma Ltd, H1 2017

Neuroblastoma – Pipeline by Trovagene Inc, H1 2017

Neuroblastoma – Dormant Projects, H1 2017

Neuroblastoma – Dormant Projects, H1 2017 (Contd..1), H1 2017

Neuroblastoma – Dormant Projects, H1 2017 (Contd..2), H1 2017

Neuroblastoma – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Neuroblastoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports